Marc Rubin - Net Worth and Insider Trading
Marc Rubin Net Worth
The estimated net worth of Marc Rubin is at least $46,613 dollars as of 2024-11-13. Marc Rubin is the Director of Galectin Therapeutics Inc and owns about 13,581 shares of Galectin Therapeutics Inc (GALT) stock worth over $40,064. Marc Rubin is the Director of Curis Inc and owns about 1,441 shares of Curis Inc (CRIS) stock worth over $5,865. Marc Rubin is also the Executive Chairman of Titan Pharmaceuticals Inc and owns about 155 shares of Titan Pharmaceuticals Inc (TTNP) stock worth over $684. Details can be seen in Marc Rubin's Latest Holdings Summary section.
Disclaimer: The insider information is derived from SEC filings. The estimated net worth is based on the final shares held after open market or private purchases and sales of common stock with a transaction code of "P" or "S" on Form 4, assuming that Marc Rubin has not made any transactions after 2019-02-22 and currently still holds the listed stock(s). Please note that this estimate may not reflect the actual net worth.
Transaction Summary of Marc Rubin
Marc Rubin Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Marc Rubin owns 4 companies in total, including Curis Inc (CRIS) , Galectin Therapeutics Inc (GALT) , and Titan Pharmaceuticals Inc (TTNP) among others .
Click here to see the complete history of Marc Rubin’s form 4 insider trades.
Insider Ownership Summary of Marc Rubin
| Ticker | Comapny | Transaction Date | Type of Owner |
|---|---|---|---|
| CRIS | Curis Inc | 2023-01-23 | director |
| GALT | Galectin Therapeutics Inc | 2020-01-09 | director |
| TTNP | Titan Pharmaceuticals Inc | 2021-02-10 | director & Executive Chairman |
 | | 2022-10-28 | director & 10 percent owner |
Marc Rubin Latest Holdings Summary
Marc Rubin currently owns a total of 3 stocks. Among these stocks, Marc Rubin owns 13,581 shares of Galectin Therapeutics Inc (GALT) as of February 22, 2019, with a value of $40,064 and a weighting of 85.95%. Marc Rubin owns 1,441 shares of Curis Inc (CRIS) as of January 23, 2019, with a value of $5,865 and a weighting of 12.58%. Marc Rubin also owns 155 shares of Titan Pharmaceuticals Inc (TTNP) as of September 21, 2018, with a value of $684 and a weighting of 1.47%.
Latest Holdings of Marc Rubin
| Ticker | Comapny | Latest Transaction Date | Shares Owned | Current Price ($) | Current Value ($) |
|---|---|---|---|---|---|
| GALT | Galectin Therapeutics Inc | 2019-02-22 | 13,581 | 2.95 | 40,064 |
| CRIS | Curis Inc | 2019-01-23 | 1,441 | 4.07 | 5,865 |
| TTNP | Titan Pharmaceuticals Inc | 2018-09-21 | 155 | 4.42 | 684 |
Holding Weightings of Marc Rubin
Marc Rubin Form 4 Trading Tracker
According to the SEC Form 4 filings, Marc Rubin has made a total of 0 transactions in Galectin Therapeutics Inc (GALT) over the past 5 years. The most-recent trade in Galectin Therapeutics Inc is the sale of 51,185 shares on February 22, 2019, which brought Marc Rubin around $308,134.
According to the SEC Form 4 filings, Marc Rubin has made a total of 0 transactions in Curis Inc (CRIS) over the past 5 years. The most-recent trade in Curis Inc is the sale of 925 shares on January 23, 2019, which brought Marc Rubin around $19,425.
According to the SEC Form 4 filings, Marc Rubin has made a total of 0 transactions in Titan Pharmaceuticals Inc (TTNP) over the past 5 years. The most-recent trade in Titan Pharmaceuticals Inc is the acquisition of 111 shares on September 21, 2018, which cost Marc Rubin around $100,000.
Insider Trading History of Marc Rubin
- 1
Marc Rubin Trading Performance
GuruFocus tracks the stock performance after each of Marc Rubin's buying transactions within different timeframes. To be detailed, the average return of stocks after 3 months bought by Marc Rubin is 58.47%. GuruFocus also compares Marc Rubin's trading performance to market benchmark return within the same time period. The performance of stocks bought by Marc Rubin within 3 months outperforms 5 times out of 6 transactions in total compared to the return of S&P 500 within the same period.
You can select different timeframes to see how Marc Rubin's insider trading performs compared to the benchmark.
Performance of Marc Rubin
Average Return
Outperforming Transactions
| 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | 3 Years | |
|---|---|---|---|---|---|---|
| Return(%) | 50.41 | | | | | |
| Relative Return to S&P 500(%) | 49.97 | | | | | |
Marc Rubin Ownership Network
Ownership Network List of Marc Rubin
Ownership Network Relation of Marc Rubin
Marc Rubin Owned Company Details
What does Curis Inc do?
Who are the key executives at Curis Inc?
Marc Rubin is the director of Curis Inc. Other key executives at Curis Inc include CDO Jonathan B. Zung , CFO Diantha Duvall , and director & President & CEO James E Dentzer .
Curis Inc (CRIS) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Curis Inc (CRIS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Curis Inc (CRIS) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Curis Inc (CRIS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Curis Inc Insider Transactions
Marc Rubin Mailing Address
Above is the net worth, insider trading, and ownership report for Marc Rubin. You might contact Marc Rubin via mailing address: C/o Titan Pharmaceuticals, Inc., 400 Oyster Point Blvd., Ste 505, San Francisco Ca 94080.
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
